{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:10:37Z","timestamp":1791090637144,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,6,28]],"date-time":"2009-06-28T00:00:00Z","timestamp":1246147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s11060-009-9948-7","type":"journal-article","created":{"date-parts":[[2009,6,27]],"date-time":"2009-06-27T08:39:48Z","timestamp":1246091988000},"page":"211-217","source":"Crossref","is-referenced-by-count":170,"title":["Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma"],"prefix":"10.1007","volume":"96","author":[{"given":"Andrew D.","family":"Norden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Raizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen R.","family":"Lamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Lassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K. Alfred","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard A.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Ian","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Dancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Prados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,28]]},"reference":[{"key":"9948_CR1","unstructured":"CBTRUS (2008) Statistical report: primary brain tumors in the United States, 2000\u20132004. Published by the Central Brain Tumor Registry of the United States"},{"key":"9948_CR2","unstructured":"Louis DN, Scheithauer BW, Budka H (2000) Meningeal tumors. In: Kleihues P, Cavenee WK (eds) WHO classification of tumors of the nervous system. IARC, Lyon, pp 175\u2013196"},{"key":"9948_CR3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jnen\/63.4.275","volume":"63","author":"K Lamszus","year":"2004","unstructured":"Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275\u2013286","journal-title":"J Neuropathol Exp Neurol"},{"key":"9948_CR4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-004-2749-0","volume":"70","author":"A Perry","year":"2004","unstructured":"Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neurooncol 70:183\u2013202. doi: 10.1007\/s11060-004-2749-0","journal-title":"J Neurooncol"},{"key":"9948_CR5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11864-004-0038-y","volume":"5","author":"KP McMullen","year":"2004","unstructured":"McMullen KP, Stieber VW (2004) Meningioma: current treatment options and future directions. Curr Treat Options Oncol 5:499\u2013509. doi: 10.1007\/s11864-004-0038-y","journal-title":"Curr Treat Options Oncol"},{"key":"9948_CR6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1227\/01.NEU.0000170980.47582.A5","volume":"57","author":"A Modha","year":"2005","unstructured":"Modha A, Gutin PH (2005) Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57:538\u2013550 discussion 538\u2013550","journal-title":"Neurosurgery"},{"key":"9948_CR7","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3171\/FOC-07\/10\/E12","volume":"23","author":"AD Norden","year":"2007","unstructured":"Norden AD, Drappatz J, Wen PY (2007) Targeted drug therapy for meningiomas. Neurosurg Focus 23:E12. doi: 10.3171\/FOC-07\/10\/E12","journal-title":"Neurosurg Focus"},{"key":"9948_CR8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00401-004-0875-6","volume":"108","author":"U Andersson","year":"2004","unstructured":"Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H, Henriksson R (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108:135\u2013142. doi: 10.1007\/s00401-004-0875-6","journal-title":"Acta Neuropathol"},{"key":"9948_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3171\/jns.1997.87.2.0315","volume":"87","author":"RS Carroll","year":"1997","unstructured":"Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, Lau N, Guha A (1997) Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87:315\u2013323","journal-title":"J Neurosurg"},{"key":"9948_CR10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0046-8177(94)90270-4","volume":"25","author":"MD Johnson","year":"1994","unstructured":"Johnson MD, Horiba M, Winnier AR, Arteaga CL (1994) The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas. Hum Pathol 25:146\u2013153. doi: 10.1016\/0046-8177(94)90270-4","journal-title":"Hum Pathol"},{"key":"9948_CR11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/1097-0142(19900701)66:1<152::AID-CNCR2820660127>3.0.CO;2-5","volume":"66","author":"NR Jones","year":"1990","unstructured":"Jones NR, Rossi ML, Gregoriou M, Hughes JT (1990) Epidermal growth factor receptor expression in 72 meningiomas. Cancer 66:152\u2013155. doi: 10.1002\/1097-0142(19900701)66:1<152::AID-CNCR2820660127>3.0.CO;2-5","journal-title":"Cancer"},{"key":"9948_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF01054768","volume":"26","author":"RM Linggood","year":"1995","unstructured":"Linggood RM, Hsu DW, Efird JT, Pardo FS (1995) TGF alpha expression in meningioma\u2014tumor progression and therapeutic response. J Neurooncol 26:45\u201351. doi: 10.1007\/BF01054768","journal-title":"J Neurooncol"},{"key":"9948_CR13","first-page":"488","volume":"177","author":"JS Sanfilippo","year":"1993","unstructured":"Sanfilippo JS, Rao CV, Guarnaschelli JJ, Woost PG, Byrd VM, Jones E, Schultz GS (1993) Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings. Surg Gynecol Obstet 177:488\u2013496","journal-title":"Surg Gynecol Obstet"},{"key":"9948_CR14","first-page":"2172","volume":"47","author":"AS Weisman","year":"1987","unstructured":"Weisman AS, Raguet SS, Kelly PA (1987) Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 47:2172\u20132176","journal-title":"Cancer Res"},{"key":"9948_CR15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.jnen.0000189834.63951.81","volume":"64","author":"M Johnson","year":"2005","unstructured":"Johnson M, Toms S (2005) Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol 64:1029\u20131036. doi: 10.1097\/01.jnen.0000189834.63951.81","journal-title":"J Neuropathol Exp Neurol"},{"key":"9948_CR16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2990.1998.00150.x","volume":"24","author":"DW Hsu","year":"1998","unstructured":"Hsu DW, Efird JT, Hedley-Whyte ET (1998) MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 24:441\u2013452. doi: 10.1046\/j.1365-2990.1998.00150.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"9948_CR17","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","volume":"366","author":"N Thatcher","year":"2005","unstructured":"Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527\u20131537. doi: 10.1016\/S0140-6736(05)67625-8","journal-title":"Lancet"},{"key":"9948_CR18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"key":"9948_CR19","doi-asserted-by":"crossref","unstructured":"Wen PY, Yung WKA, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, DeAngelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD (2006) Phase II Study of Imatinib Mesylate (Gleevec\u00ae) For Recurrent Meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro-oncol. doi: 10.1215\/15228517-2009-010","DOI":"10.1215\/15228517-2009-010"},{"key":"9948_CR20","unstructured":"Wen PY, Yung WKA, Lamborn K, et al (2006) Phase II Study of Imatinib Mesylate (STI571) For Patients With Recurrent Meningiomas (NABTC 01-08). Neuro Oncol 8: 454 [abstract]"},{"key":"9948_CR21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bjc.6603669","volume":"96","author":"E Franceschi","year":"2007","unstructured":"Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, Grosso D, Scopece L, Blatt V, Urbini B, Pession A, Tallini G, Crino L, Brandes AA (2007) Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96:1047\u20131051. doi: 10.1038\/sj.bjc.6603669","journal-title":"Br J Cancer"},{"key":"9948_CR22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","volume":"22","author":"JN Rich","year":"2004","unstructured":"Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133\u2013142. doi: 10.1200\/JCO.2004.08.110","journal-title":"J Clin Oncol"},{"key":"9948_CR23","doi-asserted-by":"crossref","unstructured":"Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL Prados M (2004) A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc ASCO 22: 1502 [abstract]","DOI":"10.1200\/jco.2004.22.90140.1502"},{"key":"9948_CR24","doi-asserted-by":"crossref","unstructured":"Van Den Bent MJ, Brandes A, Rampling R, Kouwenhoven M, Kros JM, Carpentier AF, Clement P, Klughammer B, Gorlia T, Lacombe D (2007) Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. J Clin Oncol 25: 2005 [abstract]","DOI":"10.1016\/S1359-6349(07)70906-0"},{"key":"9948_CR25","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","volume":"62","author":"MC Chamberlain","year":"2004","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62:1210\u20131212","journal-title":"Neurology"},{"key":"9948_CR26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","volume":"78","author":"MC Chamberlain","year":"2006","unstructured":"Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 78:271\u2013276. doi: 10.1007\/s11060-005-9093-x","journal-title":"J Neurooncol"},{"key":"9948_CR27","unstructured":"Grunberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, Russell C, Kabbinavar F, Barger GR Stelzer KJ (2001) Phase III Double-Blind Randomized Placebo-Controlled Study of Mifepristone (RU) for the Treatment of Unresectable Meningioma. Proc ASCO 20: 222 [abstract]"},{"key":"9948_CR28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/02688690400012392","volume":"18","author":"HB Newton","year":"2004","unstructured":"Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18:495\u2013499","journal-title":"Br J Neurosurg"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-009-9948-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-009-9948-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-009-9948-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:19:35Z","timestamp":1559348375000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-009-9948-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["9948"],"URL":"https:\/\/doi.org\/10.1007\/s11060-009-9948-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,28]]}}}